Combination Therapy of Integrin Inhibitor and Chemotherapy for Treatment of Cancer

Gilon Chaim, HUJI, Faculty of Science, The Institute of Chemistry
Hoffman Amnon, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research

Integrins are transmembrane receptors that function as adhesion and signal transduction molecules, thus transducing information “outside-in” and “inside-out”. Diverse human pathologies involve integrin adhesion including inflammation, cardiovascular, cancer, thrombotic diseases, fibrosis and infectious diseases. Nineteen of the 24 integrin heterodimers have been therapeutic targets for drug discovery. Most of them are antibody-based with the disadvantages of high cost, immunogenicity and IV administration. Six Integrin inhibitors, mainly α4-series, generated revenues of ~US$3.5b in 2016.

This technology presents a new combination treatment, composed of a proprietary cyclic peptide platform technology for oral administration of integrin inhibitors and its prodrug. This may help overcome the challenges of the current drugs and help fight immunotherapy resistant tumors.

Our innovation
The technology focuses on a combination treatment that targets different types of integrins. The treatment is characterized by:

  • A new molecule: integrin inhibitor cyclic peptide
  • A prodrug to be taken in combination with the new cyclic peptide
  • Personalized medicine for immunotherapy resistant patients

The present technology offers a new approach to target integrins, a well-established target for immunotherapy resistant tumors. The new compounds are characterized by several features which may overcome the challenges of the current integrin inhibitors drugs. Moreover, they show defined target specificity allowing reduced side effects and a low production price, with a reduced price per patient.


Patent Status

Published US 2020/0283483 A1

Contact for more information:

Keren-Or Amar
VP, Business Development, Healthcare
Contact ME: